Recon: UK halts Valneva’s chikungunya vaccine; CDC terminates all vaccine advisory committee members

• Several hundred NIH employees sign a letter of protest to the agency’s director (STAT)
• RFK Jr. removes all members of CDC panel advising U.S. on vaccines (CNBC)
• Trump’s ‘gold standard’ order is a blueprint for politicizing science (STAT)
• Trump Drug Price Plan Risks Fallout for Medicaid, Beneficiaries (Bloomberg Law)
• Senate Republicans Plan to Release Major Revisions to Trump’s Tax Bill (Bloomberg)
• NIH scientists speak out over estimated $12 billion in Trump funding cuts (Reuters)
• Pfizer CEO: no commitments made in drug price meetings with US government (Reuters)

• Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says (Reuters)
• UK's MHRA suspends Valneva's chikungunya vaccine for elderly (Reuters)
• UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say (Reuters)
• Contraceptives for poorest countries stuck in warehouses after US aid cuts (Reuters)
• Mpox is still a health emergency, WHO says (Reuters)

• A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say (STAT)
• Metsera’s amylin drug shows early potential for substantial weight loss (STAT)
• Otsuka tops Vera Therapeutics in kidney disease study showdown (STAT)
• Merck's potential blockbuster cholesterol pill succeeds in late-stage studies (Reuters)
• Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO (Reuters)
• Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up (Endpoints)
• Is there still hope for Summit's cancer drug buried in the data? (Endpoints)
• Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids (Endpoints)
• MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D (Endpoints)

• These blood tests for cancer are increasingly popular. Experts still aren’t sure how best to use them (STAT)
• As Omada goes public, executives reflect on why profits are elusive in digital health (STAT)
• Medtech Caris Life Sciences Seeks to Raise $423.5 Million in IPO (Bloomberg)
• Medtronic removes tracheostomy tubes due to dislodging risk (MedTech Dive)
• Owens & Minor spikes $1.36B Rotech buyout over regulatory barriers (MedTech Dive)
• Outset Medical appoints Renee Gaeta as CFO (MedTech Dive)
• Ultrahuman Launches Home Health Monitoring (MedTech Insight)

• Mondelez CEO sees shoppers remaining thrifty (Food Business News)
• Conagra to sell seafood brands Van de Kamp’s and Mrs Paul’s for $55M (Food Dive)
• How Nerds Gummy Clusters became a big hit in candy (Food Dive)
• California Bill Would Remove Ultra-Processed Foods from School Lunches (Food Safety)

• RFK Jr.’s chronic disease agency would eliminate or reduce funding for some prevention programs (STAT)
• Philanthropies rush to save measles surveillance network pushed to brink of collapse by U.S. cuts (STAT)
• FDA reassures rare disease advocates that ‘being flexible’ is plan for gene therapy (STAT)
• Pharma imports into the US return to normal after March tariff stockpiling (Endpoints)
• Judge rules J&J unit must pay $442M in antitrust case (MedTech Dive)